The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry

Canadian Respiratory Journal

Volumn 2016, Issue , 2016, Pages

  Ryerson, Christopher J ^a   Tan, Benjamin ^a   Fell, Charlene D ^b   Manganas, Hélène ^c   Shapera, Shane ^d   Mittoo, Shikha ^d   Sadatsafavi, Mohsen ^a,e   To, Teresa ^f   Gershon, Andrea ^d   Fisher, Jolene H ^d   Johannson, Kerri A ^b   Hambly, Nathan ^g   Khalil, Nasreen ^a   Marras, Theodore K ^d   Morisset, Julie ^c   Wilcox, Pearce G ^a   Halayko, Andrew J ^h   Khan, Mohammad Adil ⁱ   Kolb, Martin ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e VANCOUVER COASTAL HEALTH   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ARTICLE; CANADIAN; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; CLINICAL FEATURE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH CERTIFICATE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; FIBROTIC INTERSTITIAL LUNG DISEASE; FOLLOW UP; FORCED VITAL CAPACITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH STATUS; HISTORY; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG TRANSPLANTATION; LUNG VOLUME; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; OXYGEN SATURATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIROMETRY; RHEUMATOID ARTHRITIS; SELF REPORT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; VISUAL ANALOG SCALE; CANADA; CLINICAL TRIAL; MULTICENTER STUDY; REGISTER;

CANADA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; PULMONARY FIBROSIS; REGISTRIES;

EID: 84965100161     PISSN: 11982241     EISSN: 19167245     Source Type: Journal    
DOI: 10.1155/2016/3562923     Document Type: Article

References (33)

1. W. D. Travis, U. Costabel, D. M. Hansell et al. , "An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, " American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 6, pp. 733-748, 2013.
2. J. Hutchinson, A. Fogarty, R. Hubbard, and T. McKeever, "Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review, " European Respiratory Journal, vol. 46, no. 3, pp. 795-806, 2015.
3. G. Raghu, S.-Y. Chen, W.-S. Yeh et al. , "Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11, " The Lancet Respiratory Medicine, vol. 2, no. 7, pp. 566-572, 2014.
4. C. J. Ryerson, T. J. Corte, H. R. Collard, and L. Richeldi, "A global registry for idiopathic pulmonary fibrosis: the time is now, " European Respiratory Journal, vol. 44, no. 2, pp. 273-276, 2014.
5. H. R. Collard, B. B. Moore, K. R. Flaherty et al. , "Acute exacerbations of idiopathic pulmonary fibrosis, " American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 7, pp. 636-643, 2007.
6. J. W. Song, S.-B. Hong, C.-M. Lim, Y. Koh, and D. S. Kim, "Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome, " European Respiratory Journal, vol. 37, no. 2, pp. 356-363, 2011.
7. T. Kishaba, H. Tamaki, Y. Shimaoka, H. Fukuyama, and S. Yamashiro, "Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis, " Lung, vol. 192, no. 1, pp. 141-149, 2014.
8. R. Agarwal and S. K. Jindal, "Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review, " European Journal of Internal Medicine, vol. 19, no. 4, pp. 227-235, 2008.
9. T. J. Huie, A. L. Olson, G. P. Cosgrove et al. , "A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes, " Respirology, vol. 15, no. 6, pp. 909-917, 2010.
10. K. Tachibana, Y. Inoue, A. Nishiyama et al. , "Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serumIL-7 as a prognostic marker, " Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 28, no. 2, pp. 113-122, 2011.
11. V. Simon-Blancal, O. Freynet, H. Nunes et al. , "Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors, " Respiration, vol. 83, no. 1, pp. 28-35, 2012.
12. H. R. Collard, A. J. Ward, S. Lanes, D. Cortney Hayflinger, D. M. Rosenberg, and E. Hunsche, "Burden of illness in idiopathic pulmonary fibrosis, " Journal ofMedical Economics, vol. 15, no. 5, pp. 829-835, 2012.
13. H. R. Collard, S. Y. Chen, W. S. Yeh et al. , "Healthcareutilization and costs of idiopathic pulmonary fibrosis in U. S. Medicare beneficiaries aged 65 years and older, " Annals of the American Thoracic Society, vol. 12, no. 7, pp. 981-987, 2015.
14. G. Raghu, H. R. Collard, J. J. Egan et al. , "An Official ATS/ERS/ JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidencebased guidelines for diagnosis and management, " American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788-824, 2011.
15. E. G. Eakin, P. M. Resnikoff, L. M. Prewitt, A. L. Ries, and R. M. Kaplan, "Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire, " Chest, vol. 113, no. 3, pp. 619-624, 1998.
16. J. J. Swigris, M. Han, R. Vij et al. , "TheUCSDshortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis, " Respiratory Medicine, vol. 106, no. 10, pp. 1447-1455, 2012.
17. P. W. Jones, F. H. Quirk, and C. M. Baveystock, "The St George's respiratory questionnaire, " Respiratory Medicine, vol. 85, supplement 2, pp. 25-37, 1991.
18. J. Yorke, P. W. Jones, and J. J. Swigris, "Development and validity testing of an IPF-specific version of the St George's respiratory questionnaire, " Thorax, vol. 65, no. 10, pp. 921-926, 2010.
19. J. J. Swigris, K. K. Brown, J. Behr et al. , "The SF-36 and SGRQ: validity and first look at minimumimportant differences in IPF, " Respiratory Medicine, vol. 104, no. 2, pp. 296-304, 2010.
20. J. Brazier, N. Jones, and P. Kind, "Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire, " Quality of Life Research, vol. 2, no. 3, pp. 169-180, 1993.
21. R. Rabin and F. de Charro, "EQ-5D: a measure of health status fromthe EuroQol Group, " Annals ofMedicine, vol. 33, no. 5, pp. 337-343, 2001.
22. The EuroQol Group, "EuroQol-a new facility for themeasurement of health-related quality of life, " Health Policy, vol. 16, no. 3, pp. 199-208, 1990.
23. N. Bansback, A. Tsuchiya, J. Brazier, and A. Anis, "Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies, " PLoS ONE, vol. 7, no. 2, Article ID e31115, 2012.
24. N. Macintyre, R. O. Crapo, G. Viegi et al. , "Standardisation of the single-breath determination of carbon monoxide uptake in the lung, " European Respiratory Journal, vol. 26, no. 4, pp. 720-735, 2005.
25. M. R. Miller, J. Hankinson, V. Brusasco et al. , "Standardisation of spirometry, " European Respiratory Journal, vol. 26, no. 2, pp. 319-338, 2005.
26. J. Wanger, J. L. Clausen, A. Coates et al. , "Standardisation of the measurement of lung volumes, " European Respiratory Journal, vol. 26, no. 3, pp. 511-522, 2005.
27. A. E. Holland, M. A. Spruit, T. Troosters et al. , "An official European respiratory society/American thoracic society technical standard: field walking tests in chronic respiratory disease, " European Respiratory Journal, vol. 44, no. 6, pp. 1428-1446, 2014.
28. S. J. Singh, M. A. Puhan, V. Andrianopoulos et al. , "An official systematic review of the European Respiratory Society/ American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease, " European Respiratory Journal, vol. 44, no. 6, pp. 1447-1478, 2014.
29. P. L. Enright and D. L. Sherrill, "Reference equations for the sixminute walk in healthy adults, " American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 5, part 1, pp. 1384-1387, 1998.
30. A. U. Wells, S. R. Desai, M. B. Rubens et al. , "Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography, " American Journal of Respiratory & Critical Care Medicine, vol. 167, no. 7, pp. 962-969, 2003.
31. L. Richeldi, R. M. du Bois, G. Raghu et al. , "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, " The New England Journal of Medicine, vol. 370, no. 22, pp. 2071-2082, 2014.
32. P. Bedouch, C. A. Marra, J. M. FitzGerald, L. D. Lynd, and M. Sadatsafavi, "Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study, " PloS ONE, vol. 7, no. 12, Article IDe50949, 2012.
33. C. J. Ryerson, V. Cottin, K. K. Brown, and H. R. Collard, "Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm, " European Respiratory Journal, vol. 46, no. 2, pp. 512-520, 2015.